Dr. Xiaodong(Sheldon) Cao joined Chengdu New Radiomedicine Technology Co., Ltd. in 2023. He is the Executive President and President of Pharmaceutical Research Institute of the company.

Dr. Cao is a PhD in Chemistry from Universität Konstanz, Germany. D and holds a bachelor's degree anda master's degree in Medicinal Chemistry from Peking University. Dr. Cao was a Postdoctoral Fellow at Gilead Sciences, Senior Scientist at Ontogen Corporation, Associate Director of R&D at LG Biomedical Research Institute, Project Leader (Principal Scientist) at Takeda Pharmaceuticals in San Diego, Head of R&D Project Management at Cerep Shanghai, CEO of Zova Biotherapeutics, and Founder and CEO of Eubulus Biotherapeutics.

With more than 30 years of experiences in the field of innovative pharmaceutical development, he has led the efforts for ZV0203, an Antibody Drug-Conjugate (ADC) from project initiation to IND both with NMPA and FDA; he was a core member of R&D team for several registered drugs and small- molecule-drugs at clinical stage. Dr. Cao is an expert in protein structure-based drug design and drug delivery, with experiences in therapeutic areas of oncology, metabolism, and anti-viral.